Sancho Juan-Manuel, Ribera Josep-Maria, Romero Maria-José, Martín-Reina Victoria, Giraldo Pilar, Ruiz Elena
Hematology Department, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona.
Haematologica. 2006 Mar;91(3):ECR02.
The depot formulation of liposomal cytarabine (DepoCyte) has proven to be useful as intrathecal (IT) treatment of neoplastic and lymphomatous meningitis. We report the results of compassionate use of DepoCyte in 6 patients diagnosed with acute leukemia (AL) and CNS involvement. Two patients had CNS involvement at diagnosis and the remaining 4 had CNS relapse. Three patients received DepoCyte as adjuvant therapy and achieved complete response whereas 2 out of the remaining 3 cases treated with DepoCyte as the only drug showed sustained response. The side effects were mild and manageable in all patients. These findings justify the development of clinical trials to evaluate the efficacy and safety of IT depot cytarabine in meningeal involvement of AL.
脂质体阿糖胞苷（DepoCyte）的长效剂型已被证明可有效用于鞘内（IT）治疗肿瘤性和淋巴瘤性脑膜炎。我们报告了对6例诊断为急性白血病（AL）并伴有中枢神经系统（CNS）受累患者同情用药使用DepoCyte的结果。2例患者在诊断时即有CNS受累，其余4例出现CNS复发。3例患者接受DepoCyte作为辅助治疗并获得完全缓解，而其余3例中2例将DepoCyte作为唯一药物治疗显示出持续缓解。所有患者的副作用均轻微且可控。这些发现为开展临床试验以评估IT长效阿糖胞苷在AL脑膜受累中的疗效和安全性提供了依据。
